KR101525948B1 - Composition comprising carob extract for preventing, improving menopause of man - Google Patents
Composition comprising carob extract for preventing, improving menopause of man Download PDFInfo
- Publication number
- KR101525948B1 KR101525948B1 KR1020140177696A KR20140177696A KR101525948B1 KR 101525948 B1 KR101525948 B1 KR 101525948B1 KR 1020140177696 A KR1020140177696 A KR 1020140177696A KR 20140177696 A KR20140177696 A KR 20140177696A KR 101525948 B1 KR101525948 B1 KR 101525948B1
- Authority
- KR
- South Korea
- Prior art keywords
- symptoms
- extract
- composition
- carob
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 235000013912 Ceratonia siliqua Nutrition 0.000 title claims abstract description 31
- 240000008886 Ceratonia siliqua Species 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 230000009245 menopause Effects 0.000 title description 8
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 18
- 230000003247 decreasing effect Effects 0.000 claims abstract description 12
- 206010029216 Nervousness Diseases 0.000 claims abstract description 8
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 201000001881 impotence Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 206010016825 Flushing Diseases 0.000 claims abstract description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 230000035946 sexual desire Effects 0.000 claims abstract description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 14
- 229960003604 testosterone Drugs 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010058359 Hypogonadism Diseases 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 abstract description 4
- 210000002307 prostate Anatomy 0.000 abstract description 3
- 230000004970 emotional disturbance Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000036760 body temperature Effects 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000000605 extraction Methods 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 210000001596 intra-abdominal fat Anatomy 0.000 description 8
- 230000037406 food intake Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 244000000626 Daucus carota Species 0.000 description 6
- 235000002767 Daucus carota Nutrition 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010002261 Androgen deficiency Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940008396 carrot extract Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000131329 Carabidae Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- -1 fluoroalkane Chemical compound 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000037209 prostate health Effects 0.000 description 2
- 208000026455 prostate symptom Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065369 Burnout syndrome Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/804—Low calorie, low sodium or hypoallergic
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 예방 및 개선용 조성물에 관한 것이다.
이에 따라, 갱년기 남성에게서 발생하는 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소와 같은 증상들을 개선시킬 수 있다.The present invention relates to a composition for preventing and improving menopausal symptoms comprising carob extract as an active ingredient.
Thus, there is a need for a method of treating a patient suffering from prostate hyperplasia, lower urinary tract symptoms, nervous irritation, emotional disturbance, depression, facial flushing, sleeping disorder, vitality loss, decreased work capacity, loss of sexual desire, erectile dysfunction, Such as a decrease in body weight, a decrease in body temperature, and the like.
Description
본 발명은 캐롭 추출물의 새로운 용도에 관한 것으로, 더욱 상세하게는 캐롭 추출물을 유효성분으로 포함하여 갱년기 남성에게서 나타나는 증상을 예방 및 개선하기 위한 조성물에 관한 것이다.
The present invention relates to a new use of carob extract, and more particularly, to a composition for preventing and improving the symptoms of menopausal men including carob extract as an active ingredient.
일반적으로 갱년기는 여성의 폐경 이후에 여성 호르몬 부족으로 나타나는 각종 증상들이 발생하는 시기를 일컫는 용어로서, 폐경이 발생하지 않는 남성과는 무관했다. 그러나 남성 역시 나이가 들어감에 따라 남성 호르몬의 분비가 감소하기 때문에 이와 관련된 여러 증상들이 나타나는데, 근래에는 이러한 남성 역시 갱년기라 지칭하고, 주로 50대 남성에게서 발생한다.In general, menopause is a term that refers to the period when various symptoms of female hormone deficiency occur after women's menopause, and it has nothing to do with men who do not develop menopause. However, men also show a decrease in the secretion of male hormones as they get older, and many other related symptoms are present. In recent years, these men are also referred to as menopause, mainly in fifties.
남성 갱년기의 경우, 피로감, 기억력 저하, 우울증, 체지방 증가, 골밀도 감소, 발기부전, 성욕저하증 등과 같은 증상이 나타나는데, 만약 과도한 음주와 흡연, 스트레스 등의 외적인 요소가 부가된다면 위와 같은 증상들이 더욱 촉진된다. 더욱이 고령의 남성의 경우 대다수가 고혈압이나 당뇨와 같은 성인병이 있어 문제는 더욱 심각해진다.In men, menopausal symptoms are fatigue, depression, depression, increased body fat, decreased bone density, impotence, and hypogonadism. These symptoms are further promoted if external factors such as excessive drinking, smoking, and stress are added . Furthermore, the majority of elderly men have serious problems such as hypertension or adult diseases such as diabetes.
한편, 남성 갱년기 증상을 치료하기 위한 수단으로는 대표적으로 호르몬 요법이 쓰이고 있다. 호르몬 요법은 부족한 남성 호르몬을 인위적으로 보충해주는 요법으로서, 그 효과가 좋은 것으로 알려져 있으나, 만약 남성 갱년기 증상과 유사하다는 이유만으로 위 치료방법을 시행할 경우 심각한 부작용을 초래할 수 있고, 또한 신체 특성상 인위적인 호르몬 보충으로 부작용이 발생한 사례가 많아 그 사용에 있어 전문가의 정확한 진단이 요구된다.On the other hand, hormone therapy is typically used as a means of treating male menopausal symptoms. Hormone therapy is an artificial supplement to deficient male hormones and is known to be effective. However, if the above-mentioned treatment method is used merely because it is similar to male menopausal symptoms, serious side effects may be caused. In addition, Many side effects have occurred as a supplement, requiring accurate diagnosis by experts.
따라서 남성 호르몬의 감소로 인한 증상을 치료하거나 예방할 수 있고, 부작용을 최소화시키는 천연 물질을 이용한 조성물에 대한 연구 및 개발이 필요한데, 본 발명자들은 남성 호르몬 조절 이상 증후군 및 이로 인한 증상의 개선 효능이 뛰어난 새로운 천연성분에 관하여 연구하던 중 캐롭{Ceratonia siliqua (L.) Taub.} 추출물이 남성의 갱년기로 인한 증상을 개선하는 것을 확인하여 본 발명을 완성했다.Therefore, it is necessary to research and develop a composition using a natural substance which can treat or prevent symptoms due to the decrease of male hormone and minimize side effects. The inventors of the present invention have found that a male hormone control syndrome and a novel While studying natural ingredients, carob { Ceratonia siliqua (L.) Taub.} The present inventors confirmed that the extract improves the symptoms caused by the menopausal period of the male, thereby completing the present invention.
캐롭은 콩과에 속하는 상록 활엽 관목으로, 가뭄에 잘 견디며, 잎에 수지를 함유하고 있다. 이러한 캐롭이 남성의 갱년기 증상과 관련하여 어떠한 효과가 있는지에 대하여는 연구된 바가 없다.
Carob is an evergreen broad-leaved shrub belonging to the soybean family, tolerates drought, and contains resin in the leaves. There has been no study of the effect of these carrots on menopausal symptoms.
본 발명에서 해결하고자 하는 과제는 갱년기 남성에서 발생하는 증상을 효과적으로 완화시킬 수 있고, 천연성분으로 이루어져 신체에 거부반응을 최소화시킬 수 있는 캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 예방 및 개선용 조성물을 제공하는 것이다.
The object of the present invention is to provide a composition for preventing and improving menopausal symptoms, which comprises a carob extract which can effectively alleviate symptoms occurring in menopausal men and can minimize rejection to the body, .
위와 같은 과제를 해결하기 위한 본 발명에 따른 조성물은 캐롭 추출물을 유효성분으로 포함하는 것을 기술적 특징으로 한다.
In order to solve the above-mentioned problems, the composition according to the present invention is characterized by including carob extract as an active ingredient.
본 발명에 따른 캐롭 추출물을 유효성분으로 포함하는 조성물은 갱년기 남성에게서 발생하는 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소와 같은 증상들을 개선시킬 수 있다.
The composition comprising the carotenoid extract according to the present invention as an active ingredient can be used for the treatment of menopausal symptoms such as enlargement of the prostate gland, lower urinary tract symptoms, nervous irritation, emotional anxiety, depression, facial flushing, sleeping disorder, Erectile dysfunction, diminished tack, decreased physical fitness, reduced exercise capacity, and reduced body hair.
도 1은 시험대상동물의 체중 증가량 측정 결과를 나타낸 그래프
도 2는 시험대상동물의 내장지방 무게 측정 결과를 나타낸 그래프
도 3은 혈중 테스토스테론 농도 측정 결과를 나타낸 그래프
도 4는 IPSS 검사법으로 측정된 시험대상남성의 전립선 비대증 및 하부요로증상 개선율을 나타낸 그래프
도 5는 AMS 검사법으로 측정된 시험대상남성의 갱년기 증상 개선율을 나타낸 그래프 1 is a graph showing the results of measurement of weight gain of an animal under test
Fig. 2 is a graph showing the results of visceral fat weight measurement
3 is a graph showing the results of blood testosterone concentration measurement
FIG. 4 is a graph showing the improvement rate of the enlarged prostate and lower urinary tract symptoms in the test subjects measured by the IPSS test method
FIG. 5 is a graph showing the rate of improvement in menopausal symptom in the test subjects measured by the AMS test method
본 발명을 설명하기에 앞서 본 발명에서 사용되는 용어의 의미를 설명한다.Before describing the present invention, the meaning of terms used in the present invention will be described.
본 명세서에서 '추출물'은 당업계에서 조추출물(Crude extract)로 통용되는 의미이지만, 광의적으로는 추출물을 추가적으로 분획(Fractionation)한 분획물의 의미도 포함한다. 즉, 캐롭 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예를 들어, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 캐롭 추출물에 포함되는 것이다.In the present specification, 'extract' means to be used as a crude extract in the art, but broadly also includes the meaning of fractions in which the extract is further fractionated. That is, the carob extract includes not only those obtained using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, the extract may be fractionated by passing it through an ultrafiltration membrane having a constant molecular weight cut-off value, or by separation by various chromatographies (prepared for separation by size, charge, hydrophobicity or affinity) Fractions obtained through various purification methods are also included in the carob extract of the present invention.
본 명세서에서 '유효성분으로 포함하는'이란 캐롭 추출물의 효능이나 활성을 달성하는데 충분한 양을 포함하는 것을 의미한다. 본 발명은 천연식물재료인 캐롭으로부터 추출한 조성물로서, 과량 투여하여도 인체에 부작용이 없으므로 캐롭 추출물이 본 발명의 조성물에 포함된 양적 상한은 통상의 기술자가 적절한 범위 내에서 선택하여 실시할 수 있다.As used herein, "comprising as an active ingredient" means containing an amount sufficient to achieve the potency or activity of the carob extract. The present invention is a composition extracted from carrots, which is a natural plant material, and there is no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the carrots extract contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.
본 명세서에서 '약학적 유효량'은 캐롭 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.
By "pharmaceutically effective amount" herein is meant an amount sufficient to achieve the potency or activity of the carob extract.
남성 갱년기는 여성 갱년기와 유사하게 중년의 남성에게서 나타나는 여러 증상들을 통칭하는 것으로, 외부적으로 나타나는 증상으로는 피로감, 기억력 저하, 우울증, 체지방 증가, 골밀도 감소, 발기부전, 성욕저하증, 하부요로증상, 성선기능저하증 등이 있으며, 내부적으로는 테스토스테론 저하증이 있다. 만약 과도한 음주와 흡연, 스트레스 등의 외적인 요소가 부가된다면 위와 같은 증상들이 더욱 촉진된다. 더욱이 고령의 남성의 경우 대다수가 고혈압이나 당뇨와 같은 성인병이 있어 문제는 더욱 심각해진다.Male menopause refers to various symptoms that appear in middle-aged men similar to women's menopause. Externals include fatigue, memory loss, depression, increased body fat, decreased bone density, impotence, lower urinary tract symptoms, Hypogonadism and hypothyroidism. If the external factors such as excessive drinking, smoking, and stress are added, the above symptoms are further promoted. Furthermore, the majority of elderly men have serious problems such as hypertension or adult diseases such as diabetes.
아래에서는 이와 같은 남성 갱년기를 완화시키기 위한 캐롭 추출물에 대해 상세히 설명한다.
The following is a detailed description of carob extract to alleviate this menopause.
본 발명에 따른 캐롭 추출물은 유기용매를 이용하여 추출하는데, 추출용매로서 사용될 수 있는 것은 아래와 같다.The carob extract according to the present invention is extracted using an organic solvent, and the following extract solvents can be used.
우선 극성 용매로서 적합한 것은, (i) 물, (ii) 탄소수 1 내지 6의 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), (iii) 아세트산, (iv) DMFO(Dimethyl-formamide) 및 (v) DMSO(Dimethyl sulfoxide) 등이 있다.(I) water, (ii) an alcohol having 1 to 6 carbon atoms (preferably, methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, , 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) DMFO (Dimethyl-formamide) and (v) DMSO (dimethyl sulfoxide).
그리고 비극성 용매로서 적합한 것은, 아세톤, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 헥산, 2,2,4-트리메틸펜탄, 데칸, 시클로헥산, 시클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소, 메틸렌클로라이드, 석유에테르 및 THF 등이 있다.Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1 Chlorophenyl, 1-chlorobutane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, chloroform, Dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, methylene chloride, petroleum ether and THF.
본 발명은 추출용매로서, (a) 물, (b) 탄소수 1 내지 4의 무수 또는 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 부틸아세테이트, (h) 1,3-부틸렌글리콜, (i) 헥산 및 (j) 디에틸에테르 등을 사용하는 것이 바람직한데, 용이한 추출을 위해 물, 에탄올 또는 물과 에탄올의 혼합물을 캐롭에 처리하여 추출하는 것이 더욱 바람직하다.(B) a water-soluble or lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol and water, (d) ), Acetone, ethyl acetate, chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether, For easy extraction, it is more preferable to extract water, ethanol, or a mixture of water and ethanol into a carob.
또한, 본 발명에서 이용되는 캐롭 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.In addition, the carob extract used in the present invention may be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.
따라서, 본 발명은 위와 같은 추출용매를 이용하여 추출물을 제조할 수 있는데, 아래에서는 캐롭 추출물을 제조하는 방법을 설명한다.
Accordingly, the present invention can produce an extract using the above-mentioned extraction solvent. Hereinafter, a method for producing a carob extract will be described.
1)캐롭 추출물의 제조1) Preparation of carrot extract
①캐롭을 선별하여 분쇄한 뒤, ②분쇄물 중량의 약 1 내지 25배의 부피량(v/w%), 바람직하게는 7 내지 20배의 부피량의 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 더 바람직하게는 물, 에탄올 또는 이들의 혼합용매로, ③0 내지 120℃, 바람직하게는 50 내지 100℃의 추출온도에서, ④약 1시간 내지 10일, 바람직하게는 약 2시간 내지 8시간 동안, ⑤냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 또는 가열추출법 등의 추출방법으로, 바람직하게는 열수추출 또는 환류냉각 추출법으로 ⑥약 1 내지 10회, 바람직하게는 2 내지 8회 반복 추출한다. 그리고 ⑦상기 추출물을 여과포로 여과하고, ⑧여과액을 진공농축한 후 ⑨-①동결 건조하거나, ⑨-②배합비율에 따라 덱스트린을 혼합하여 분무 건조하여 캐롭 추출물을 획득한다.(1) After the carrots are selectively pulverized, (2) water containing purified water of a volume (v / w%), preferably 7 to 20 times the volume of the pulverized water, of about 1 to 25 times the weight, methanol, ethanol, Ethanol or a mixed solvent thereof, (3) at an extraction temperature of from 0 to 120 ° C, preferably from 50 to 100 ° C, and (4) For about 1 hour to 10 days, preferably for about 2 hours to 8 hours, and (5) by an extraction method such as a cold extraction, a hot water extraction, an ultrasonic extraction, a reflux cooling extraction or a heat extraction method, (6) Repeatedly extracts about 1 to 10 times, preferably 2 to 8 times. And (7) the extract is filtered with filter paper, (8) the filtrate is concentrated in vacuo, (9) freeze-dried, or (9) mixed with dextrin according to the mixing ratio to obtain a carob extract.
그리고 후술할 실험에서 사용될 캐롭 추출물은, 캐롭 열매의 분쇄물 중량 8배의 부피량의 정제수를 용매로 하여 4시간 동안 열수추출법으로 1차 추출하고, 4배의 정제수를 가하여 2차 추출한 뒤, 추출물을 여과포로 여과하고, 진공농축한 후 추출물과 덱스트린을 1:1로 혼합하여 분무 건조함으로써 제조한다.The carrot extract to be used in the experiment to be described later was obtained by primary extraction by hot water extraction method for 4 hours using purified water of a volume of 8 times the weight of the crushed powder of carob fruit as a solvent and secondary extraction by adding 4 times of purified water, Is filtered through a filter cloth, concentrated in vacuo, and then mixed with the extract and dextrin in a ratio of 1: 1 and spray-dried.
한편, 캐롭 추출물은 아임계 유체를 이용하여 추출하는 아임계 추출법이나 초임계 유체를 이용하여 추출하는 초임계 추출법을 통해 추출물을 제조하여도 무방하다.
On the other hand, the carob extract may be prepared by subcritical extraction using a subcritical fluid or supercritical extraction using a supercritical fluid.
아래에서는 본 발명에 따른 캐롭 추출물에 의한 효과를 시험예에 의해 상세히 설명한다.
Hereinafter, the effect of the carob extract according to the present invention will be described in detail with reference to test examples.
시험예Test Example
1: 동물대상시험 1: Animal test
<1-1> 시험 대상<1-1> Subjects to be tested
10주령, 체중 250g 내외의 스프라그-다우리(Sprague-Dawley) 계통의 웅성 랫트(Rat)를 대조군과 실험군으로 각각 10마리씩 분류하였다. Male Sprague-Dawley rats weighing about 250 g at 10 weeks of age were divided into 10 rats each as a control group and an experimental group.
실험군은 매일 오전 같은 시간에 50㎎/㎏의 농도로 생리식염수에 녹인 캐롭 추출물을 경구 투여하였고, 대조군은 동일 양의 생리식염수를 경구 투여했다. 참고로, 사육 조건은 온도 24±2℃, 습도 50 내지 55%, 물과 식이는 제한 없이 제공하였다.
The experimental group was orally administered carrot extract dissolved in physiological saline at a concentration of 50 mg / kg daily at the same time of day, and the control group was orally administered the same amount of physiological saline. For reference, breeding conditions were 24 ± 2 ℃, 50-55% humidity, and water and diet were provided without restriction.
<1-2> 체중 증가량 측정<1-2> Measurement of weight gain
본 발명의 조성물이 체중 증가에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.
The effect of the composition of the present invention on body weight gain was confirmed and it was confirmed whether it is effective in preventing or treating male menopausal period.
체중은 상기 <1-1> 시험 대상에서 분류된 각 군을 시험 시작일과 종료일의 동일한 시간에 체중을 측정하고, 그 증가량을 결과값으로 사용하였다. 결과는 도 1에 도시되어 있다. 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.The body weights were measured at the same time of the start and end dates of the test, and the increase was used as a result. The results are shown in FIG. Statistical analysis was performed using the Student's t-test for statistical significance, and was considered significant at p <0.05.
도 1에 도시된 바와 같이, 생리식염수만 섭취한 대조군(CTL)의 체중 증가량은 약 103g인 반면, 캐롭 추출물을 섭취한 실험군(CA)의 체중 증가량은 약 84g으로 대조군에 비해 체중 증가량이 통계적으로 유의하게 낮은 것을 확인하였다. 이를 통해 캐롭 추출물이 남성 갱년기 증상 중 하나인 체중 증가를 억제하는 효과가 있다는 것을 알 수 있다.
As shown in FIG. 1, the body weight gain of the control group (CTL) fed only with physiological saline was about 103 g, while the weight gain of the experimental group (CA) ingested with carab oil extract was about 84 g, Respectively. This shows that carab extract has the effect of inhibiting weight gain, one of the male menopausal symptoms.
<1-3> 내장지방 무게 측정<1-3> Built-in fat weight measurement
본 발명의 조성물이 내장지방 무게에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.The effect of the composition of the present invention on the visceral fat weight was confirmed and it was confirmed that it is effective in preventing or treating male menopausal period.
구체적으로, 상기 <1-1> 시험 대상에서 분류된 각 군을 마지막 경구 투여 시점으로부터 8시간 동안 절식시킨 뒤 에테르 마취하고, 개복하여 내장지방을 분리한 다음 그 무게를 측정하였다. 결과값은 대조군(CTL)의 내장지방 무게를 100%로 환산한 뒤 실험군의 내장지방 무게를 대조군(CTL)에 대한 상대 비율 값으로 나타내었다. 결과는 도 2에 도시되어 있으며, 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.Specifically, the groups classified in the <1-1> test subjects were fasted for 8 hours from the last oral administration time, and ether anesthesia was performed, and visceral fat was separated from the groups and then weighed. The results were expressed as the ratio of visceral fat in the experimental group to that of the control group (CTL) after converting the visceral fat weight of the control group (CTL) to 100%. The results are shown in FIG. 2 and statistically processed using the statistical program Student's t-test to verify the significance of the test results, and expressed as being significant at p <0.05.
도 2에 도시된 바와 같이, 캐롭 추출물을 섭취한 실험군(CA)의 내장지방 무게는 생리식염수만 섭취한 대조군(CTL)의 내장지방 무게 대비 약 66%로 확인되었다. 이를 통해 캐롭 추출물이 남성 갱년기 증상 중 하나인 내장지방 증가를 감소시키는 효과가 있다는 것을 알 수 있다.
As shown in FIG. 2, the visceral fat weight of the experimental group (CA) ingested with carob extract was found to be about 66% of the visceral fat weight of the control group (CTL) containing only physiological saline. This shows that carob extract has the effect of reducing visceral fat gain, one of the male menopausal symptoms.
<1-4> 체내 테스토스테론 측정<1-4> Measurement of testosterone in the body
본 발명의 조성물이 혈중 남성호르몬의 양에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.It was confirmed that the composition of the present invention has an effect on the amount of male hormone in the blood, and thus it is confirmed that the composition is effective for preventing or treating menopausal period.
구체적으로, 상기 <1-1> 시험 대상에서 분류된 각 군을 경구 투여 전 시점과 마지막 경구 투여 시점에서 8시간 동안 절식시킨 뒤 에테르 마취하고, 개복하여 복대정맥으로부터 혈액을 채취하였다. 이렇게 채취된 경구 투여 전과 후의 혈액을 각각 헤파린(Heparin)이 처리된 튜브로 옮긴 뒤 원심분리(2,500rpm, 15min, 4℃)하여 혈장을 분리하였다. 그리고 분리된 혈장에 스테로이드 대체제(Steroid displacement reagent)를 처리한 후, 면역분석 키트(R&D Systems, 미국)를 이용하여 혈중 총 테스토스테론 함량을 측정하였다. 결과값은 투여 전 혈장 테스토스테론 함량 대비 값으로 나타내었다. 결과는 도 3에 도시되어 있으며, 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.Specifically, each group of the <1-1> subjects to be tested was fasted for 8 hours before the oral administration and at the last oral administration, and then anesthetized with ether, and blood was collected from the abdominal vein. Before and after the oral administration, the blood was transferred to a heparin-treated tube, and the plasma was separated by centrifugation (2,500 rpm, 15 min, 4 ° C). Steroid displacement reagent was then applied to the separated plasma and total serum testosterone content was measured using an immunoassay kit (R & D Systems, USA). The results were expressed as a value relative to the plasma testosterone content before administration. The results are shown in FIG. 3 and were statistically processed using the statistical program Student's t-test to verify the significance of the test results, and were considered to be significant at p < 0.05.
도 3에 도시된 바와 같이, 생리식염수만 섭취한 대조군(CTL)은 투여 후 통계적으로 유의한 변화가 나타나지 않은 반면, 캐롭 추출물을 섭취한 실험군(CA)은 투여 전에 비해 약 46%의 혈중 테스토스테론 수치가 증가하였다. 이를 통해 캐롭 추출물이 혈중 테스토스테론 농도 증가에 영향을 미친다는 것을 알 수 있다.
As shown in FIG. 3, the control group (CTL) fed only with physiological saline did not show statistically significant change after the administration, whereas the test group (CA) ingested with the carob extract showed a blood testosterone level of about 46% . This suggests that the carotenoid extract has an effect on blood testosterone levels.
시험예Test Example
2: 인체대상시험 2: Human body test
<2-1> 시험 대상<2-1> Subjects to be tested
본 검사에 동의한 만 40세 이상의 남성 30명을 대조군과 실험군으로 각 15명씩 임의로 분류하여 대조군은 위약(Placebo)을 섭취하게 하였고, 실험군은 캐롭 추출물을 일일 40mg씩 4주 동안 섭취하도록 하였다.
Thirty male subjects aged 40 or older who agreed to this test were randomly divided into control group and experimental group. Each control group received placebo and carrots were administered 40 mg / kg / day for 4 weeks.
<2-2> 전립선증상 점수 설문조사<2-2> Prostate Symptom Score Questionnaire
I-PSS(International Prostate symptom score, 국제전립선증상점수)는 전립선 건강 저하로 인해 나타날 수 있는 하부요로증상 및 그에 따른 삶의 불편함을 객관적으로 평가하기 위해 고안된 검사이다. IPSS는 세계 각국의 언어로 번역되어 타당성이 입증되어 전세계적으로 사용되고 있으며, 국내에서도 검사법의 타당성과 신뢰도가 입증되어 현재 우리나라의 전립선 건강 평가에 사용되는 대표적인 검사법으로 각 항목은 표 1과 같다.The International Prostate Symptom Score (I-PSS) is a test designed to objectively assess the lower urinary tract symptoms and the resulting discomfort associated with prostate health. IPSS has been translated into languages of the world and has been validated and used globally. In Korea, the validity and reliability of the test method have been proved and the representative test method used in Korean prostate health evaluation is shown in Table 1.
만족Extremely
satisfied
섭취 전과 후의 IPSS 점수 개선율이 계산된 결과가 도 4에 도시되어 있다. 결과는 통계프로그램 SPSS(version 12.0)로 통계 처리하여 p<0.05 수준으로 유의성을 검증하였다.The results of calculating the IPSS score improvement rate before and after ingestion are shown in FIG. Results were statistically analyzed by SPSS (version 12.0), and significance was confirmed at p <0.05 level.
도 4에 도시된 바와 같이 대조군(Placebo)은 IPSS 점수가 2.8% 가량 변화한 반면, 캐롭 추출물 섭취군(실험군)은 IPSS 점수가 약 48% 이상 감소되어 전립선 비대증과 하부요로증상이 효과적으로 개선됨이 확인되었다. 이로써 본 발명의 조성물인 캐롭 추출물이 남성 갱년기에서 나타날 수 있는 전립선 비대증, 하부요로증상 개선에 효과가 있음을 알 수 있다.
As shown in FIG. 4, the IPSS score of the control group (placebo) was changed by 2.8%, while the ingestion of carob extract decreased the IPSS score by about 48%, indicating that the enlargement of the prostate gland and the lower urinary tract were effectively improved . Thus, it can be seen that the carob extract, which is a composition of the present invention, is effective in improving benign prostatic hyperplasia and lower urinary tract symptoms which may appear in male menopausal period.
<2-3> 한글판 AMS(<2-3> Korean version of AMS AgingAging Males'Males' SymptomSymptom ))
1999년 Heinemann 등(Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A New 'Aging Male's Symptom'(AMS) Scale. The Aging Male 1992, 2:105-114.)이 독일어로 개발한 AMS 등급은 노화가 남성의 삶의 질에 미치는 영향을 객관적으로 평가하기 위해 고안된, 타당도와 신뢰도가 입증된 도구로, 한국판은 2003년 김세현의 번역판이 타당도와 신뢰도가 입증되었다(Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, et al. e Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003;1:77.). 한글판 AMS는 표 2와 같이 전체 17개의 문항으로 이루어져 있으며 모든 항목은 증상 없음(1점), 가벼움(2점), 보통(3점), 심함(4점) 및 매우 심함(5점)으로 정량화된다. 총점 27점 이상인 경우를 양성으로 판정하며, 증상 정도에 따라 17-26점은 없음(No), 27-36점은 경도(Little), 37-49점은 중등도(Moderate), 50점 이상을 중증(Severe)으로 구분한다. AMS 17개 문항은 각각 항목에 따라서 증상별로 설문항목을 갱년기의 대표적 증상인 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력 감소, 체력저하, 운동능력감소, 체모감소로 분류하여 평가할 수 있다.The AMS rating developed in this German language is based on the age of the aging process, which is characterized by aging (eg, aging, depression, anxiety and depression). In 1999, Heinemann et al. (Heinemann LAJ, Zimmermann T, Vermeulen A, (Daig I, Heinemann LA, Kim S, Kwon S, Lee JH, Kim JH, Kim JH, Kim JH, Leungwattanaki S, Badia X, Myon E, et al. Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. The Korean version of AMS is composed of 17 items as shown in Table 2. All items are quantified as no symptom (1 point), lightness (2 points), normal (3 points), severe (4 points) do. A score of 27 points or more was judged to be positive. According to the degree of symptom, 17-26 points were absent (No), 27-36 points were mild (Little), 37-49 points were moderate, (Severe). AMS 17 items were classified into symptom-based questionnaire items such as nervousness, emotional anxiety, depression, facial flushing, sleeping disorder, vitality depression, decreased work ability, sexual desire, erectile dysfunction, Decrease in exercise capacity, and decrease in body hair.
대조군 및 실험군의 AMS 결과는 항목별 개선율 및 전체 개선율로 표 3 및 도 5에 도시되어 있고, 결과값은 평균과 표준편차로 기입하였으며, 통계프로그램 스튜던트 t-테스트(Student's t-test)로 통계처리하여 p<0.05 시에 유의한 것으로 간주하였다.The AMS results of the control group and the experimental group are shown in Table 3 and FIG. 5 as the improvement rate and the overall improvement rate by item, and the results were written as mean and standard deviation. The statistical program was statistically processed by Student's t-test And were considered to be significant at p <0.05.
증상
Symptom
AMS 문항번호
AMS question number
개선율
Improvement rate
시험 결과, 대조군의 AMS 점수가 섭취 전후 크게 차이가 없는 반면, 본 조성물 섭취군은 섭취 전에 비해 AMS 점수에서 약 57% 이상의 남성 갱년기 증상 개선율을 보였다. 또한 각 항목별 증상 개선율을 확인한 결과, 각 항목에 해당하는 증상들이 전체적으로 개선되는 것을 확인하였다. 이로써 캐롭 추출물이 중년 남성에서 나타는 다양한 남성갱년기 증상을 전반적으로 완화시킴을 확인하였다.
As a result of the test, the AMS score of the control group was not significantly different before and after the ingestion, whereas the intake group of the composition showed an improvement in the menopausal symptom of about 57% or more in the AMS score before the ingestion. In addition, the symptom improvement rate of each item was checked, and it was confirmed that symptoms corresponding to each item improved overall. These results suggest that carob extract generally alleviates the various menopausal symptoms in middle-aged men.
<2-4> 한글판 <2-4> Localization ADAMADAM (( AndrogenAndrogen DeficiencyDeficiency inin AgingAging MalesMales ) )
2000년 Morley 등(Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49:1239-1242.)이 자신들의 임상경험을 근거로 대표적인 10가지 증상들을 확인하여 남성 호르몬 결핍을 평가하기 위해 개발한 검사지로서 40세 이상의 남성에서 남성호르몬 결핍 상태를 선별할 수 있는 진단검사로서 타당성이 입증되었다. 문항수가 그리 많지 않고, 진단의 민감도가 높아 남성호르몬 결핍 선별검사로 흔히 이용된다. 한글판 ADAM 검사지는 김수웅 등{김수웅, 오승준, 백재승, 김세철. Androgen Deficiency in Aging Males(ADAM) 설문지의 한국어 번역본 개발. 대한비뇨기과학회지 2004, 45(7):674-679.}이 남성 갱년기 환자들을 선별하고 이를 임상연구에 활용할 수 있도록 영어판을 한글판으로 번역한 검사지이다. ADAM의 10개 문항은 각각의 증세에 대해 '예' 또는 '아니오'로 대답할 수 있게 되어있으며, 성기능의 저하 또는 그 밖의 증상 유무를 평가함으로써 남성호르몬 결핍 여부를 평가할 수 있는 검사이다. 검사항목 중 문항 1 또는 7에서 '예'라고 답하거나, 1번과 7번 문항을 제외한 항목에서 3개 이상 '예'라고 답한 경우 남성 호르몬 결핍 증세가 있어 남성갱년기 증세가 있다고 볼 수 있다.In 2000, Morley et al. (Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P McCready D et al., Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49: 1239-1242) , Which was developed to evaluate male hormone deficiency by examining 10 representative symptoms based on clinical experience of men and women over 40 years of age. The number of questions is low and the sensitivity of diagnosis is high, so it is often used as a test for sex hormone deficiency. The ADAM test site in Korea is Kim Soo-woong (Kim Su-woong, Oh Seung-joon, Baek Jae-seung, Development of a Korean translation of the Androgen Deficiency in Aging Males (ADAM) Questionnaire. The Korean Journal of Urology 2004, 45 (7): 674-679.) This is an English-language version of the Korean version of the manuscript for screening male menopausal women and using them for clinical research. The ADAM's 10 questions are able to answer "Yes" or "No" to each symptom and are tests that can assess male hormone deficiency by assessing sexual dysfunction or other symptoms. If you answer 'Yes' in question 1 or 7 of the test items, or if you answered 'Yes' to more than 3 items in items other than items 1 and 7, you may have menopausal symptoms because of male hormone deficiency.
캐롭 추출물을 섭취한 실험군과 위약을 섭취한 대조군의 ADAM 결과는 표 4의 검사지를 기준으로 남성갱년기 유병률(%)이 의심되는 사람의 비율로 나타내었다. 실험군 및 대조군의 섭취 전과 후의 남성갱년기 유병률은 표 5에 기재되어 있고, 결과값은 평균과 표준편차로 기입하였으며, 통계프로그램 스튜던트 t-테스트(Student's t-test)로 통계처리하여 p<0.05 시에 유의한 것으로 간주하였다. (* p<0.05 vs. 섭취 전)The ADAM results of the carrots extract and the placebo-treated control rats were expressed as the percentage of men suspected of having menopausal age (%) based on the table in Table 4. The male pre-menopausal prevalence before and after intake of the experimental group and the control group is shown in Table 5 and the results are expressed as means and standard deviation and statistically treated with the Student's t-test statistical program at p <0.05 Were considered significant. (* p <0.05 vs. before ingestion)
시험 결과, 대조군에서는 위약 섭취 전후 ADAM 검사지로 평가한 남성갱년기 유병률에 큰 변화가 없는 반면, 캐롭 조성물을 섭취한 실험군은 섭취 후 ADAM 검사지로 평가한 남성갱년기 유병률이 약 38% 감소하였다. 따라서 본 발명의 조성물은 남성호르몬 결핍 증세를 완화시켜 남성 갱년기 증상을 호전시킨다는 것을 알 수 있다.In the control group, there was no significant change in male menopausal prevalence as assessed by the ADAM test before and after the placebo intake, whereas in the experimental group consuming the carob composition, the menopausal prevalence estimated by the ADAM test was reduced by 38%. Therefore, it can be seen that the composition of the present invention alleviates the symptoms of male hormone deficiency and improves male menopausal symptoms.
Claims (4)
A food composition for prevention and improvement of male menopausal symptoms comprising carob extract as an active ingredient.
A pharmaceutical composition for preventing and treating male menopausal symptoms comprising carob extract as an active ingredient.
상기 남성 갱년기 증상은 테스토스테론 저하증인 것을 특징으로 하는 조성물.
The method according to claim 1 or 2,
Wherein the male menopausal symptoms are testosterone hypoglycemia.
상기 남성 갱년기 증상은 성선기능저하증, 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소 중 어느 하나인 것을 특징으로 하는 조성물.The method according to claim 1 or 2,
The male menopausal symptoms may include hypogonadism, prostatic hypertrophy, lower urinary tract symptoms, nervousness, emotional anxiety, depression, facial flushing, sleeping disorder, dysfunctional vitality, decreased work capacity, loss of sexual desire, erectile dysfunction, A decrease in ability, and a decrease in body hair.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140177696A KR101525948B1 (en) | 2014-12-10 | 2014-12-10 | Composition comprising carob extract for preventing, improving menopause of man |
JP2017550441A JP6430659B2 (en) | 2014-12-10 | 2015-12-10 | A composition for preventing and improving menopause, comprising carob extract as an active ingredient |
PCT/KR2015/013512 WO2016093637A1 (en) | 2014-12-10 | 2015-12-10 | Composition for preventing and improving andropause, comprising carob extract as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140177696A KR101525948B1 (en) | 2014-12-10 | 2014-12-10 | Composition comprising carob extract for preventing, improving menopause of man |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101525948B1 true KR101525948B1 (en) | 2015-06-05 |
Family
ID=53500068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140177696A Expired - Fee Related KR101525948B1 (en) | 2014-12-10 | 2014-12-10 | Composition comprising carob extract for preventing, improving menopause of man |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6430659B2 (en) |
KR (1) | KR101525948B1 (en) |
WO (1) | WO2016093637A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220104542A (en) * | 2021-01-18 | 2022-07-26 | 주식회사 네이처센스 | COMPOSITION FOR pain relief AND PREVENTING OR ALLEVIATING STRESS-INVOLVED DISEASE COMPRISING Extract of CANNABIS SATIVA L. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050119134A (en) * | 2003-03-21 | 2005-12-20 | 넥스메드 홀딩스 인코포레이티드 | Prostaglandin compositions for the treatment of erectile dysfunction |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5102916A (en) * | 1990-07-03 | 1992-04-07 | Jacques Antoun | Method of relieving gastric ulcers with carob extract |
US5229136A (en) * | 1992-05-21 | 1993-07-20 | Clintec Nutrition Co. | Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients |
US6763229B2 (en) * | 2001-05-02 | 2004-07-13 | Koninklijke Philips Electronics N.V. | Timing recovery switching for an adaptive digital broadband beamforming (antenna diversity) for ATSC terrestrial DTV based on segment sync detection |
GB0213612D0 (en) * | 2002-06-13 | 2002-07-24 | Novartis Nutrition Ag | Organic compounds |
FR2954697B1 (en) * | 2009-12-24 | 2016-11-04 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING CAROBLE EXTRACT AS ACTIVE ACTIVATOR OF AQUAPORIN EXPRESSION |
CN111518866A (en) * | 2011-03-01 | 2020-08-11 | 群体创新有限责任公司 | Materials and methods for treating conditions associated with pathogenic biofilms |
KR101460126B1 (en) * | 2012-02-10 | 2014-11-10 | 주식회사 바이오그랜드 | Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient |
KR101460125B1 (en) * | 2013-02-05 | 2014-11-11 | 주식회사 바이오그랜드 | Composition for preventing and improving andropause syndrome and aging of male comprising rooibos extract as an active ingredient |
FR3005392B1 (en) * | 2013-05-07 | 2015-09-18 | United Pharmaceuticals | ANTI-REGURGITATION COMPOSITION PRESERVING INTESTINAL TRANSIT |
-
2014
- 2014-12-10 KR KR1020140177696A patent/KR101525948B1/en not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2017550441A patent/JP6430659B2/en not_active Expired - Fee Related
- 2015-12-10 WO PCT/KR2015/013512 patent/WO2016093637A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050119134A (en) * | 2003-03-21 | 2005-12-20 | 넥스메드 홀딩스 인코포레이티드 | Prostaglandin compositions for the treatment of erectile dysfunction |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220104542A (en) * | 2021-01-18 | 2022-07-26 | 주식회사 네이처센스 | COMPOSITION FOR pain relief AND PREVENTING OR ALLEVIATING STRESS-INVOLVED DISEASE COMPRISING Extract of CANNABIS SATIVA L. |
KR102489407B1 (en) * | 2021-01-18 | 2023-01-17 | 주식회사 네이처센스 | COMPOSITION FOR pain relief AND PREVENTING OR ALLEVIATING STRESS-INVOLVED DISEASE COMPRISING Extract of CANNABIS SATIVA L. |
Also Published As
Publication number | Publication date |
---|---|
JP2018500393A (en) | 2018-01-11 |
JP6430659B2 (en) | 2018-11-28 |
WO2016093637A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Laadim et al. | Ethnopharmacological survey of plants used for the treatment of diabetes in the town of Sidi Slimane (Morocco) | |
JP6898905B2 (en) | Composition for prevention, treatment and improvement of dysuria containing Indian pepper extract | |
KR101563577B1 (en) | Functional composition for improving, preventing hypoestrogenism of women experiencing menopause | |
EP3534925A2 (en) | Combination therapies with cannabis plant extract | |
CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
Araújo et al. | Parkinsonia aculeata (Caesalpineaceae) improves high-fat diet-induced insulin resistance in mice through the enhancement of insulin signaling and mitochondrial biogenesis | |
KR101525948B1 (en) | Composition comprising carob extract for preventing, improving menopause of man | |
US12029775B2 (en) | Composition comprising pollen and/or pistil extracts, preparation process and associated uses | |
CN101095716A (en) | Use of Eucommia total polysaccharides in the preparation of medicines for preventing and treating systemic lupus erythematosus | |
KR100786122B1 (en) | Anti-obesity and therapeutic compositions containing herbal extracts | |
KR101621072B1 (en) | Compositions for Preventing or Treating Andropause-related Symptoms | |
KR101400913B1 (en) | Pharmaceutical composition and food composition for preventing, treating or improving woman hormone controlling disorder | |
CN104379156A (en) | Extracts from mother-of-thyme and the use thereof | |
US6428822B1 (en) | Extracts of mixed arctium lappa L., carrot and whole radish for treating hypertension, constipation and detoxification | |
CN101268831A (en) | Truffle hydrophilic solvent extract and application of the same in preparing food, health food, and medicament for treating prostate gland disease etc. | |
KR20150038906A (en) | Pharmaceutical Composition Comprising Herbal Extracts for Preventing or Treating late Onset Hypogonadism and Functional Food Comprising This Extracts | |
CN102578579B (en) | Blood sugar and blood lipid regulating health-care food and preparation method thereof | |
CN109247528A (en) | It is a kind of to subtract the composition and its application of effect for alleviating thyroid nodule and first | |
US10869495B2 (en) | Functional composition for improvement and prevention of estrogen deficiency in menopausal women | |
CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
KR20170076081A (en) | composition for improving erectile dysfunction and increasing the concentration of testosterone in blood | |
KR101511700B1 (en) | Composition for improving a atopy epidermal inflammation and manufacturing method thereof | |
KR101620079B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome comprising Smilax glabra extract or a mixture of Smilax glabra extract and Lepidium meyenii extractas | |
Von Noorden | Clinical treatises on the pathology and therapy of disorders of metabolism and nutrition v. 7, 1904-10 | |
CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20141210 |
|
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20141219 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20141210 Comment text: Patent Application |
|
PA0302 | Request for accelerated examination |
Patent event date: 20141223 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20141210 Patent event code: PA03021R01I Comment text: Patent Application |
|
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150313 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20150529 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20150529 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20180515 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20180515 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190520 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20190520 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20220516 Start annual number: 8 End annual number: 8 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240309 |